Hedera Dx is dedicated to transforming oncology by providing cutting-edge liquid biopsy solutions that improve patient experiences, outcomes and journeys, as well as healthcare professional experiences, while facilitating the prescription, discovery and development of the next breakthrough precision oncology therapies.

Hedera Dx aims to make liquid biopsies globally accessible for patients, enabling routine use of validated liquid biopsies in-house without compliance, bioinformatics, and reporting hurdles at all stages of the disease. They adopt both a customer- and a patient-centric approach, systematically integrating patient-reported outcomes and experience measures as well as customer feedback to deliver products and services that meet the needs of patients and healthcare providers.

The company provides a unique customer experience by partnering with laboratories and clinicians to offer fast, locally CE-IVDR compliant and clinically actionable next-generation sequencing (NGS) based liquid biopsies to be processed in-house. Their solutions include registered CE-IVD medical device software Hedera Prime and a pan-cancer targeted assay Hedera Profiling 2 ctDNA test panel, which integrates swiftly into existing laboratory settings.

Hedera Dx supports the growing clinical body of evidence for in-house liquid biopsy testing, including the first European prospective multicenter clinical validation study EMPATHY NSCLC, enabling real-world assessment of NGS-based liquid biopsies practices in hospital laboratories.

The team is backed by leading investors and includes experienced professionals in genetics, precision oncology, engineering, bioinformatics, sales, and finance. The company culture is based on thinking differently, being ambitious, benevolent, and human, with a commitment to enjoy their work and celebrate success as a team.